For many years, scientists have debated one of the biggest questions in Alzheimer’s disease research: if doctors remove amyloid plaques from the brain, can they actually slow the disease itself?
A rare new study suggests the answer may be yes.
By examining the brain of a person who received an anti-amyloid treatment before passing away, researchers discovered that areas where amyloid plaques had been successfully cleared were also largely protected from another damaging protein called tau.
This finding offers some of the strongest human evidence yet that removing amyloid early may slow the biological changes that eventually lead to memory loss and dementia.
Alzheimer’s disease is the leading cause of dementia worldwide. It slowly damages memory, thinking, language, and the ability to perform everyday activities. Although age is the biggest risk factor, the disease develops over many years before symptoms appear. During this silent period, harmful proteins slowly build up inside the brain.
The first of these proteins is beta-amyloid. It forms sticky clumps called plaques between nerve cells. The second protein is tau, which forms twisted tangles inside brain cells.
Scientists have found that while amyloid appears early in the disease, tau is more closely linked to the death of brain cells and the worsening of memory and thinking problems.
Several new Alzheimer’s drugs have been developed to remove amyloid plaques. Medicines such as lecanemab and donanemab have shown that they can clear amyloid from the brain, but researchers have continued asking whether this plaque removal truly changes the course of the disease.
Because very few treated patients have donated their brains for detailed examination after death, direct evidence has been extremely limited.
Researchers at the Perelman School of Medicine at the University of Pennsylvania were given a unique opportunity to study the brain of a man in his fifties who had participated in an Alzheimer’s clinical trial. He had mild cognitive impairment caused by Alzheimer’s disease and had received an experimental anti-amyloid treatment while he was alive.
When the research team carefully examined his brain, they found an unusual pattern. Some areas had been almost completely cleared of amyloid plaques, while neighboring areas still contained large amounts of amyloid. This natural contrast allowed the scientists to compare nearby brain regions that had responded differently to the same treatment.
The results were remarkable. Regions where amyloid plaques had disappeared contained very little tau and showed much less inflammation and nerve cell damage. Nearby regions where amyloid remained had far more tau tangles, greater inflammation, and stronger signs of ongoing neurodegeneration. The differences were so clear that they closely matched brain scans collected while the patient was still alive.
These findings support a long-standing theory that amyloid helps trigger the spread of tau throughout the brain. Once tau begins accumulating, it appears to drive much of the damage responsible for memory decline. By removing amyloid before large amounts of tau develop, doctors may be able to interrupt this harmful chain of events and slow disease progression.
The researchers also point out that the full benefits of treatment may take years to become obvious. Most Alzheimer’s drug trials have followed patients for only about 18 months, but slowing the buildup of tau may produce increasing benefits over much longer periods.
At the same time, the scientists emphasize that this study involved only one individual. It cannot prove exactly how much amyloid must be removed to protect the brain or guarantee that every patient will experience the same benefit. Larger studies involving more patients will be needed to confirm these observations.
Even with these limitations, experts believe the findings are highly important because they provide rare direct human evidence linking amyloid removal with reduced tau buildup. Future research will investigate why some parts of the brain clear amyloid more effectively than others and whether treatment before symptoms appear could delay or even prevent Alzheimer’s disease.
The study was presented at the 2026 Alzheimer’s Association International Conference and published simultaneously in JAMA.
If you care about Alzheimer’s disease, please read studies about the protective power of dietary antioxidants against Alzheimer’s, and eating habits linked to higher Alzheimer’s risk.
For more health information, please see recent studies that oral cannabis extract may help reduce Alzheimer’s symptoms, and Vitamin E may help prevent Parkinson’s disease.
Source: University of Pennsylvania Perelman School of Medicine.
